Pomerantz Law Firm Launches Investigation for Valneva SE Investors Following Safety Concerns
On September 8, 2025, Pomerantz LLP announced an investigation into claims concerning Valneva SE (NASDAQ: VALN) and whether the company, along with certain executives, may have participated in securities fraud or other illegal business practices. This inquiry aims to protect the interests of shareholders amidst troubling news affecting the company's stock performance.
The investigation comes in the wake of significant events that have raised red flags about the safety of Valneva's chikungunya vaccine, IXCHIQ. On February 25, 2025, the Centers for Disease Control and Prevention (CDC) indicated that it was investigating multiple hospitalizations linked to cardiac or neurological issues in individuals aged 65 and over who had received the vaccine. This alarming announcement prompted a drop in Valneva's stock price, which fell to $6.75 per American Depositary Receipt (ADR) by February 28, representing a decline of 13.57% over just four trading sessions.
The situation worsened when, on August 22, 2025, the U.S. Food and Drug Administration (FDA) announced a suspension of the marketing application for IXCHIQ due to escalating safety concerns. Following this critical news, Valneva's ADR price took a further hit, plummeting to $9.43 per ADR, down 18.99% by August 25.
Pomerantz LLP, well-respected for its expertise in corporate and securities class action litigation, emphasizes its commitment to represent investors whose interests may have been compromised. Founded by Abraham L. Pomerantz, a trailblazer in securities class actions, the firm has a rich history of advocating for victims of corporate misconduct and recovering billions in damages for individuals and shareholders alike.
As the legal landscape evolves, it's crucial for Valneva's investors to understand their rights. Should you be an affected investor or have information relating to Valneva's business practices, it is advised to reach out to Pomerantz LLP. Claims can be directed to attorney Danielle Peyton via email or phone, helping to potentially secure compensation for losses incurred. As the investigation unfolds, updates will be provided to the public and affected stakeholders.
In conclusion, investors must stay informed about their investments, especially in light of recent safety disclosures regarding Valneva's vaccine. The scrutiny surrounding this case is a pivotal moment for investors who seek justice against possible corporate missteps that may have affected their investments severely. With the ongoing investigation, there remains hope for accountability and restoration for wounded shareholders during this turbulent time.
The investigation comes in the wake of significant events that have raised red flags about the safety of Valneva's chikungunya vaccine, IXCHIQ. On February 25, 2025, the Centers for Disease Control and Prevention (CDC) indicated that it was investigating multiple hospitalizations linked to cardiac or neurological issues in individuals aged 65 and over who had received the vaccine. This alarming announcement prompted a drop in Valneva's stock price, which fell to $6.75 per American Depositary Receipt (ADR) by February 28, representing a decline of 13.57% over just four trading sessions.
The situation worsened when, on August 22, 2025, the U.S. Food and Drug Administration (FDA) announced a suspension of the marketing application for IXCHIQ due to escalating safety concerns. Following this critical news, Valneva's ADR price took a further hit, plummeting to $9.43 per ADR, down 18.99% by August 25.
Pomerantz LLP, well-respected for its expertise in corporate and securities class action litigation, emphasizes its commitment to represent investors whose interests may have been compromised. Founded by Abraham L. Pomerantz, a trailblazer in securities class actions, the firm has a rich history of advocating for victims of corporate misconduct and recovering billions in damages for individuals and shareholders alike.
As the legal landscape evolves, it's crucial for Valneva's investors to understand their rights. Should you be an affected investor or have information relating to Valneva's business practices, it is advised to reach out to Pomerantz LLP. Claims can be directed to attorney Danielle Peyton via email or phone, helping to potentially secure compensation for losses incurred. As the investigation unfolds, updates will be provided to the public and affected stakeholders.
In conclusion, investors must stay informed about their investments, especially in light of recent safety disclosures regarding Valneva's vaccine. The scrutiny surrounding this case is a pivotal moment for investors who seek justice against possible corporate missteps that may have affected their investments severely. With the ongoing investigation, there remains hope for accountability and restoration for wounded shareholders during this turbulent time.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.